Why the study?
Following the 2019 SCAI cardiogenic shock classification, it was hypothesized that IABP use may have different benefits for patients across different stages of cardiogenic shock complicating acute myocardial infarction.
Does intra-aortic balloon pump (IABP) reduce in-hospital mortality in patients with acute myocardial infarction complicating cardiogenic shock?
Does intra-aortic balloon pump (IABP) reduce in-hospital mortality in patients with acute myocardial infarction complicating cardiogenic shock?
Answers are grounded in this paper and cite their sources.
IABP may offer mortality benefits specifically in SCAI stage C cardiogenic shock complicating acute myocardial infarction, suggesting a stage-specific approach to mechanical circulatory support.
BACKGROUND: In 2012, the randomised trial IABP SHOCK II demonstrated that IABP did not reduce 30-day mortality in patients with acute myocardial infarction complicating cardiogenic shock (CS). However, SCAI proposed a new standardised classification of cardiogenic shock in 2019. It is reasonably hypothesised that the use of IABP may have different benefits for patients in different stages of CS. METHODS: = 32). In-hospital mortality was compared between using and without using IABP at each stage. CONCLUSIONS: For patients with acute myocardial infarction complicating cardiogenic shock, IABP has no effect on in-hospital mortality in SCAI stages B, D, and E. However, in SCAI stage C, IABP can reduce in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: